In the latest trading session, Aquestive Therapeutics (AQST) closed at $2.65, marking a -1.67% move from the previous day. The stock's change was less than the S&P 500's daily loss of 0.6%. Meanwhile, the Dow lost 0.17%, and the Nasdaq, a tech-heavy index, lost 0.92%.Shares of the specialty pharmaceutical company have appreciated by 7.37% over the course of the past month, outperforming the Medical sector's gain of 4.52% and the S&P 500's gain of 3.56%.The investment community will be closely monitoring the ...

The clinical trial data show that epinephrine delivered via orally administered Anaphylm™ (epinephrine) Sublingual Film is comparable to epinephrine delivered via autoinjector or manual intramuscular (IM) injection.Anaphylm candidate, with the potential to be the first and only non-invasive, orally delivered epinephrine product, demonstrates clinical results comparable to autoinjectors (such as EpiPen® and Auvi-Q®) for the emergency treatment of severe allergic reactions, including anaphylaxis. A Phase 3 pi ...

Aquestive Therapeutics (AQST) closed at $2.68 in the latest trading session, marking a +1.13% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.96%. Elsewhere, the Dow saw an upswing of 0.4%, while the tech-heavy Nasdaq appreciated by 1.3%.Heading into today, shares of the specialty pharmaceutical company had lost 0.19% over the past month, lagging the Medical sector's gain of 1.18% and the S&P 500's gain of 3.69% in that time.The upcoming earnings release of Aquestive ...

Aquestive Therapeutics (AQST) ended the recent trading session at $2.68, demonstrating a +1.52% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 0.06%. Meanwhile, the Dow gained 0.13%, and the Nasdaq, a tech-heavy index, added 0.24%.Shares of the specialty pharmaceutical company have appreciated by 3.13% over the course of the past month, underperforming the Medical sector's gain of 3.52% and the S&P 500's gain of 6.45%.Market participants will be cl ...

The latest trading session saw Aquestive Therapeutics (AQST) ending at $2.63, denoting a -1.5% adjustment from its last day's close. This change lagged the S&P 500's daily gain of 1.07%. Elsewhere, the Dow gained 0.35%, while the tech-heavy Nasdaq added 1.74%.Heading into today, shares of the specialty pharmaceutical company had gained 18.14% over the past month, outpacing the Medical sector's gain of 4.02% and the S&P 500's gain of 2.93% in that time.The investment community will be paying close attention ...

WARREN, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13th. The Aquestive team will hold a fireside chat on February 13th at 3:20 pm ET and will host investor meetings. A webcast of the f ...

Aquestive Therapeutics (AQST) closed at $2.39 in the latest trading session, marking a +0.84% move from the prior day. The stock's performance was ahead of the S&P 500's daily loss of 0.07%. Elsewhere, the Dow gained 0.16%, while the tech-heavy Nasdaq lost 0.36%.Shares of the specialty pharmaceutical company have appreciated by 18.5% over the course of the past month, outperforming the Medical sector's gain of 1.45% and the S&P 500's gain of 3.05%.The investment community will be closely monitoring the perf ...

The latest trading session saw Aquestive Therapeutics (AQST) ending at $2.50, denoting a -0.4% adjustment from its last day's close. This change lagged the S&P 500's 0.29% gain on the day. On the other hand, the Dow registered a loss of 0.25%, and the technology-centric Nasdaq increased by 0.43%.The the stock of specialty pharmaceutical company has risen by 25.5% in the past month, leading the Medical sector's gain of 2.29% and the S&P 500's gain of 2.08%.The investment community will be closely monitoring ...

Flex Point Security Aquestive Therapeutics (NASDAQ:AQST) is quickly approaching a key topline data readout for the Anaphylm (epinephrine) sublingual film that is slated for Q1 of this year. The company announced in December that they have commenced the first patient dosing in its Phase III pivotal study evaluating Anaphylm’s pharmacokinetics “PK” and pharmacodynamics “PD”. If the data is positive, Anaphylm would be heading towards a possible NDA in 2024 as a groundbreaking oral epinephrine candidate in ...

In the latest trading session, Aquestive Therapeutics (AQST) closed at $2.63, marking a -1.13% move from the previous day. This change lagged the S&P 500's 0.56% loss on the day. Elsewhere, the Dow saw a downswing of 0.25%, while the tech-heavy Nasdaq depreciated by 0.59%.The the stock of specialty pharmaceutical company has risen by 34.77% in the past month, leading the Medical sector's gain of 3.8% and the S&P 500's gain of 1.2%.Market participants will be closely following the financial results of Aquest ...